DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing blood sugar groups KELOWNA, BC / ...

Novo Nordisk NVO announced positive top-line data from a late-stage cardiovascular outcomes study that evaluated its oral ...

Bernstein said Novo Nordisk’s (NVO) recently released SOUL study results for Rybelsus in the reduction of major ...

On October 21, Novo Nordisk announced positive news on the cardiovascular benefits of its oral glucagon-like peptide-1 ...

As Novo Nordisk’s injectable diabetes-obesity duo Ozempic and Wegovy grab all the limelight, an oral version of the ...

Novo Nordisk's SOUL trial reveals a 14% reduction in major cardiovascular events with oral semaglutide in patients with type ...

In Novo Nordisk’s randomized clinical trial, semaglutide reduced the risk for major adverse cardiovascular events by 14% ...

Novo Nordisk on Monday reported the oral version of its drug semaglutide reduced the risk of major adverse cardiovascular events in adults with type 2 diabetes by 14% in a large Phase III trial.

The medicine, which Novo sells as Rybelsus, cut the risk of cardiovascular complications by 14% when added to standard therapies in people with diabetes and heart disease.

Yet another therapy with FDA accelerated approval suffers a setback; Sage’s tough year continues; Sanofi drops $326 million ...

Rybelsus (semaglutide) is a prescription drug used to manage blood sugar levels in adults with type 2 diabetes. Rybelsus can cause mild to severe side effects that may include constipation and ...

Discover how Novo Nordisk's GLP-1 medication, Rybelsus, reduces major adverse cardiovascular events by 14% in a phase 3 trial, with plans for an expanded label.